Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | DNM2 | P50570 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187610 | 1.00 | HRH3 (0.43) | HRH3DNM2HRH4PDGFRBPDGFRA | |
| SCHEMBL2567744 | 0.77 | DNM2 (0.64) | HRH3DNM2HRH4NUDT1 | |
| SCHEMBL3198280 | 0.75 | PDGFRB (0.44) | HRH4PDGFRBPDGFRAGABBR2GABBR1 | |
| SCHEMBL3198284 | 0.75 | PDGFRB (0.44) | HRH4PDGFRBPDGFRAGABBR2GABBR1 | |
| SCHEMBL3195429 | 0.70 | HRH4 (0.63) | HRH3HRH4NUDT1 | |
| SCHEMBL3195421 | 0.70 | HRH4 (0.63) | HRH3HRH4NUDT1 | |
| SCHEMBL12605112 | 0.69 | HRH3 (0.54) | HRH3DNM2HRH4NUDT1 | |
| SCHEMBL3209288 | 0.69 | CYP2D6 (0.64) | HRH3DNM2HRH4 | |
| SCHEMBL16369780 | 0.68 | GBA1 (0.44) | PDGFRBPDGFRAGABBR2GABBR1 | |
| SCHEMBL19116038 | 0.68 | NUDT1 (0.58) | HRH4PDGFRBPDGFRANUDT1GABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | claimed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | HRH3 3/4885DNM2 3882/4885HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.